BioDelivery Sciences International Inc. (NASDAQ:BDSI) rose 2.9% during mid-day trading on Tuesday . The company traded as high as $2.55 and last traded at $2.46, with a volume of 559,026 shares trading hands. The stock had previously closed at $2.39.

BDSI has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Cantor Fitzgerald cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating and decreased their price target for the company from $9.00 to $5.00 in a report on Wednesday, May 11th. FBR & Co restated a “buy” rating on shares of BioDelivery Sciences International in a report on Thursday, May 12th. Janney Montgomery Scott restated a “hold” rating and set a $4.00 price target on shares of BioDelivery Sciences International in a report on Tuesday, July 12th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $4.00 price target (down from $6.00) on shares of BioDelivery Sciences International in a report on Thursday, May 12th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. BioDelivery Sciences International presently has a consensus rating of “Buy” and an average target price of $8.25.

The company’s market capitalization is $133.99 million. The company’s 50-day moving average price is $2.43 and its 200 day moving average price is $3.00.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.31). The business earned $5 million during the quarter, compared to analyst estimates of $3.35 million. The firm’s quarterly revenue was up 194.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.37) earnings per share. On average, equities research analysts forecast that BioDelivery Sciences International Inc. will post ($1.17) EPS for the current fiscal year.

An institutional investor recently raised its position in BioDelivery Sciences International stock. Royce & Associates LLC raised its stake in shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) by 6.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,487,800 shares of the specialty pharmaceutical company’s stock after buying an additional 87,200 shares during the period. Royce & Associates LLC owned about 2.83% of BioDelivery Sciences International worth $7,127,000 at the end of the most recent quarter.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.